Cargando…
COVID-19 Vaccination in Cancer Patients Older Than 70 Years Undergoing Active Treatment. Seroconversion Rate and Safety
Patients with cancer have a high risk of intubation, intensive care unit admission, or death from the coronavirus disease (COVID-19); age and comorbidities are additional risk factors. Vaccination is effective against COVID-19; however, patients with cancer have been excluded from pivotal clinical t...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878129/ https://www.ncbi.nlm.nih.gov/pubmed/35214623 http://dx.doi.org/10.3390/vaccines10020164 |
_version_ | 1784658589177085952 |
---|---|
author | Cavanna, Luigi Proietto, Manuela Citterio, Chiara Anselmi, Elisa Zaffignani, Elena Stroppa, Elisa Maria Borsotti, Maria Teresa Contini, Andrea Di Girolamo, Gabriella Quitadamo, Vincenzo Matteo Bacchetta, Nicoletta Muroni, Monica Brescia, Maria Grazia Delledonne, Marco |
author_facet | Cavanna, Luigi Proietto, Manuela Citterio, Chiara Anselmi, Elisa Zaffignani, Elena Stroppa, Elisa Maria Borsotti, Maria Teresa Contini, Andrea Di Girolamo, Gabriella Quitadamo, Vincenzo Matteo Bacchetta, Nicoletta Muroni, Monica Brescia, Maria Grazia Delledonne, Marco |
author_sort | Cavanna, Luigi |
collection | PubMed |
description | Patients with cancer have a high risk of intubation, intensive care unit admission, or death from the coronavirus disease (COVID-19); age and comorbidities are additional risk factors. Vaccination is effective against COVID-19; however, patients with cancer have been excluded from pivotal clinical trials for COVID-19 vaccines. Data on COVID-19 vaccination in cancer patients who are older are lacking. This observational study was conducted to evaluate the seropositivity rate and safety of a two-dose regimen of the BNT162b2 or mRNA1273 vaccine in older patients (age ≥ 70 years) with solid tumors or with hematological malignances who are undergoing active anticancer treatment or whose treatment has been terminated within 6 months of vaccination. The control group was composed of healthy volunteers that were age-matched with the patient group. The primary endpoint was the seropositivity rate, and the secondary endpoints were safety, the factors influencing seroconversion, the IgG titers of patients versus healthy volunteers, and post-vaccine COVID-19 infection between 20 March 2021 and 14 July 2021. At our Institution (Oncology and Hematology Department, Hospital of Piacenza, North Italy), 443 patients with cancer underwent a program for COVID-19 vaccination; 115 (25.95%) were older than 70 (range 71–86 years) and form the basis of this study. All 115 patients accepted the vaccination. There were 64 female patients (55.65%), 94 patients (81.74%) with solid tumors, and 21 patients (18.26%) with hematological malignances. The primary endpoint of seropositivity was observed in 75 patients (65.22%)—70.21% in patients with solid tumors and 42.86% in patients with hematological malignances—versus in 100% of patients in the control group. Of the secondary endpoints, no grade 3–4 side effects and no COVID-19 infections were reported. The factor influencing seroconversion was the type of cancer. The patients’ median IgG titers were significantly lower than in the control groups. The COVID-19 vaccines BNT162b2 and mRNA1273 were effective and safe among older patients with cancer when administered in real-world conditions. |
format | Online Article Text |
id | pubmed-8878129 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88781292022-02-26 COVID-19 Vaccination in Cancer Patients Older Than 70 Years Undergoing Active Treatment. Seroconversion Rate and Safety Cavanna, Luigi Proietto, Manuela Citterio, Chiara Anselmi, Elisa Zaffignani, Elena Stroppa, Elisa Maria Borsotti, Maria Teresa Contini, Andrea Di Girolamo, Gabriella Quitadamo, Vincenzo Matteo Bacchetta, Nicoletta Muroni, Monica Brescia, Maria Grazia Delledonne, Marco Vaccines (Basel) Article Patients with cancer have a high risk of intubation, intensive care unit admission, or death from the coronavirus disease (COVID-19); age and comorbidities are additional risk factors. Vaccination is effective against COVID-19; however, patients with cancer have been excluded from pivotal clinical trials for COVID-19 vaccines. Data on COVID-19 vaccination in cancer patients who are older are lacking. This observational study was conducted to evaluate the seropositivity rate and safety of a two-dose regimen of the BNT162b2 or mRNA1273 vaccine in older patients (age ≥ 70 years) with solid tumors or with hematological malignances who are undergoing active anticancer treatment or whose treatment has been terminated within 6 months of vaccination. The control group was composed of healthy volunteers that were age-matched with the patient group. The primary endpoint was the seropositivity rate, and the secondary endpoints were safety, the factors influencing seroconversion, the IgG titers of patients versus healthy volunteers, and post-vaccine COVID-19 infection between 20 March 2021 and 14 July 2021. At our Institution (Oncology and Hematology Department, Hospital of Piacenza, North Italy), 443 patients with cancer underwent a program for COVID-19 vaccination; 115 (25.95%) were older than 70 (range 71–86 years) and form the basis of this study. All 115 patients accepted the vaccination. There were 64 female patients (55.65%), 94 patients (81.74%) with solid tumors, and 21 patients (18.26%) with hematological malignances. The primary endpoint of seropositivity was observed in 75 patients (65.22%)—70.21% in patients with solid tumors and 42.86% in patients with hematological malignances—versus in 100% of patients in the control group. Of the secondary endpoints, no grade 3–4 side effects and no COVID-19 infections were reported. The factor influencing seroconversion was the type of cancer. The patients’ median IgG titers were significantly lower than in the control groups. The COVID-19 vaccines BNT162b2 and mRNA1273 were effective and safe among older patients with cancer when administered in real-world conditions. MDPI 2022-01-21 /pmc/articles/PMC8878129/ /pubmed/35214623 http://dx.doi.org/10.3390/vaccines10020164 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Cavanna, Luigi Proietto, Manuela Citterio, Chiara Anselmi, Elisa Zaffignani, Elena Stroppa, Elisa Maria Borsotti, Maria Teresa Contini, Andrea Di Girolamo, Gabriella Quitadamo, Vincenzo Matteo Bacchetta, Nicoletta Muroni, Monica Brescia, Maria Grazia Delledonne, Marco COVID-19 Vaccination in Cancer Patients Older Than 70 Years Undergoing Active Treatment. Seroconversion Rate and Safety |
title | COVID-19 Vaccination in Cancer Patients Older Than 70 Years Undergoing Active Treatment. Seroconversion Rate and Safety |
title_full | COVID-19 Vaccination in Cancer Patients Older Than 70 Years Undergoing Active Treatment. Seroconversion Rate and Safety |
title_fullStr | COVID-19 Vaccination in Cancer Patients Older Than 70 Years Undergoing Active Treatment. Seroconversion Rate and Safety |
title_full_unstemmed | COVID-19 Vaccination in Cancer Patients Older Than 70 Years Undergoing Active Treatment. Seroconversion Rate and Safety |
title_short | COVID-19 Vaccination in Cancer Patients Older Than 70 Years Undergoing Active Treatment. Seroconversion Rate and Safety |
title_sort | covid-19 vaccination in cancer patients older than 70 years undergoing active treatment. seroconversion rate and safety |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878129/ https://www.ncbi.nlm.nih.gov/pubmed/35214623 http://dx.doi.org/10.3390/vaccines10020164 |
work_keys_str_mv | AT cavannaluigi covid19vaccinationincancerpatientsolderthan70yearsundergoingactivetreatmentseroconversionrateandsafety AT proiettomanuela covid19vaccinationincancerpatientsolderthan70yearsundergoingactivetreatmentseroconversionrateandsafety AT citteriochiara covid19vaccinationincancerpatientsolderthan70yearsundergoingactivetreatmentseroconversionrateandsafety AT anselmielisa covid19vaccinationincancerpatientsolderthan70yearsundergoingactivetreatmentseroconversionrateandsafety AT zaffignanielena covid19vaccinationincancerpatientsolderthan70yearsundergoingactivetreatmentseroconversionrateandsafety AT stroppaelisamaria covid19vaccinationincancerpatientsolderthan70yearsundergoingactivetreatmentseroconversionrateandsafety AT borsottimariateresa covid19vaccinationincancerpatientsolderthan70yearsundergoingactivetreatmentseroconversionrateandsafety AT continiandrea covid19vaccinationincancerpatientsolderthan70yearsundergoingactivetreatmentseroconversionrateandsafety AT digirolamogabriella covid19vaccinationincancerpatientsolderthan70yearsundergoingactivetreatmentseroconversionrateandsafety AT quitadamovincenzomatteo covid19vaccinationincancerpatientsolderthan70yearsundergoingactivetreatmentseroconversionrateandsafety AT bacchettanicoletta covid19vaccinationincancerpatientsolderthan70yearsundergoingactivetreatmentseroconversionrateandsafety AT muronimonica covid19vaccinationincancerpatientsolderthan70yearsundergoingactivetreatmentseroconversionrateandsafety AT bresciamariagrazia covid19vaccinationincancerpatientsolderthan70yearsundergoingactivetreatmentseroconversionrateandsafety AT delledonnemarco covid19vaccinationincancerpatientsolderthan70yearsundergoingactivetreatmentseroconversionrateandsafety |